These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 7652491)
21. Standardization activities for harmonization of test results. Dati F; Brand B Clin Chim Acta; 2000 Jul; 297(1-2):239-49. PubMed ID: 10841925 [TBL] [Abstract][Full Text] [Related]
22. External quality assessment of immunoassays of peptide hormones and tumour markers: principles and practice. Seth J; Sturgeon CM; al-Sadie R; Hanning I; Ellis AR Ann Ist Super Sanita; 1991; 27(3):443-52. PubMed ID: 1809063 [TBL] [Abstract][Full Text] [Related]
23. Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper. Duffy MJ; van Rossum LG; van Turenhout ST; Malminiemi O; Sturgeon C; Lamerz R; Nicolini A; Haglund C; Holubec L; Fraser CG; Halloran SP Int J Cancer; 2011 Jan; 128(1):3-11. PubMed ID: 20824704 [TBL] [Abstract][Full Text] [Related]
24. Guidelines for organisation and management of external quality assessment using proficiency testing. Expert Panel on Cytometry of the International Council for Standardization in Haematology. England JM; Rowan RM; van Assendelft OW; Bull BS; Coulter WH; Fujimoto K; Groner W; van Hove L; Jones AR; Kanter RJ; Klee G; Koepke JA; Lewis SM; d'Onofrio G; Tatsumi N; McLaren CE Int J Hematol; 1998 Jul; 68(1):45-52. PubMed ID: 9713167 [TBL] [Abstract][Full Text] [Related]
25. Guidelines of the Office International des Epizooties for laboratory quality evaluation, for international reference standards for antibody assays and for laboratory proficiency testing. Rev Sci Tech; 1998 Aug; 17(2):600-31. PubMed ID: 9713900 [TBL] [Abstract][Full Text] [Related]
26. [Progress in the traceability of tumor marker detection]. Ke X; Shen LS Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Apr; 55(4):545-550. PubMed ID: 33858070 [TBL] [Abstract][Full Text] [Related]
27. Tumour-Associated Autoantibodies as Diagnostic Biomarkers for Breast Cancer: A Systematic Review and Meta-Analysis. Xia J; Shi J; Wang P; Song C; Wang K; Zhang J; Ye H Scand J Immunol; 2016 Jun; 83(6):393-408. PubMed ID: 26991924 [TBL] [Abstract][Full Text] [Related]
28. Interpretative comments and reference ranges in EQA programs as a tool for improving laboratory appropriateness and effectiveness. Sciacovelli L; Zardo L; Secchiero S; Zaninotto M; Plebani M Clin Chim Acta; 2003 Jul; 333(2):209-19. PubMed ID: 12849907 [TBL] [Abstract][Full Text] [Related]
29. Usefulness of novel tumour markers. Rhodes JM Ann Oncol; 1999; 10 Suppl 4():118-21. PubMed ID: 10436801 [TBL] [Abstract][Full Text] [Related]
30. Why do immunoassays for tumour markers give differing results?--a view from the UK National External Quality Assessment Schemes. Sturgeon CM; Seth J Eur J Clin Chem Clin Biochem; 1996 Sep; 34(9):755-9. PubMed ID: 8891529 [TBL] [Abstract][Full Text] [Related]
31. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. American Society of Clinical Oncology J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171 [TBL] [Abstract][Full Text] [Related]
32. Prenatal screening for fetal aneuploidy in singleton pregnancies. Chitayat D; Langlois S; Douglas Wilson R; ; J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752 [TBL] [Abstract][Full Text] [Related]
34. Updated UK Recommendations for HER2 assessment in breast cancer. Rakha EA; Pinder SE; Bartlett JM; Ibrahim M; Starczynski J; Carder PJ; Provenzano E; Hanby A; Hales S; Lee AH; Ellis IO; J Clin Pathol; 2015 Feb; 68(2):93-9. PubMed ID: 25488926 [TBL] [Abstract][Full Text] [Related]
35. Standards for plasma and serum proteomics in early cancer detection: a needs assessment report from the national institute of standards and technology--National Cancer Institute Standards, Methods, Assays, Reagents and Technologies Workshop, August 18-19, 2005. Barker PE; Wagner PD; Stein SE; Bunk DM; Srivastava S; Omenn GS Clin Chem; 2006 Sep; 52(9):1669-74. PubMed ID: 16840585 [TBL] [Abstract][Full Text] [Related]
36. Does the assessment of serum markers in patients with lung cancer aid in the clinical decision making process? Ebert W; Muley T; Drings P Anticancer Res; 1996; 16(4B):2161-8. PubMed ID: 8694537 [TBL] [Abstract][Full Text] [Related]
37. Medicolegal affairs. International Academy of Cytology Task Force summary. Diagnostic Cytology Towards the 21st Century: An International Expert Conference and Tutorial. Frable WJ; Austin RM; Greening SE; Collins RJ; Hillman RL; Kobler TP; Koss LG; Mitchell H; Perey R; Rosenthal DL; Sidoti MS; Somrak TM Acta Cytol; 1998; 42(1):76-119; discussion 120-32. PubMed ID: 9479326 [TBL] [Abstract][Full Text] [Related]
38. Establishment of a central laboratory serum tumor marker service on a consolidated immunodiagnostic platform: development of practice standards, service improvements, and operational efficiency. Sluss PM; Lee-Lewandrowski E; Flood J; Eichbaum Q; Lewandrowski K Clin Leadersh Manag Rev; 2004; 18(1):25-31. PubMed ID: 14968750 [TBL] [Abstract][Full Text] [Related]